期刊
BLOOD
卷 115, 期 9, 页码 1727-1734出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-06-225417
关键词
-
类别
资金
- Bayer/Talecris/CBS/HQ Partnership Fund
Several clinical studies done with intravenous immunoglobulin (IVIg)-treated autoimmune patients as well as several in vitro studies have revealed that IVIg can reduce polyclonal T-cell activation and modify their cytokine secretion pattern. However, their effect on (auto) antigen-specific T-cell responses has never been addressed directly. In the present work, we used an in vivo model of induction of antigen-specific T-cell responses and an in vitro antigen presentation system to study the effects of IVIg on T-cell responses. The results obtained showed that IVIg inhibited both the in vivo and in vitro antigen-specific T-cell responses but that this effect was the indirect consequence of a reduction in the antigen presentation ability of antigen-presenting cells. The inhibitory effect of IVIg was Fc gamma RIIb-independent, suggesting that IVIg must interfere with activating Fc gamma Rs expressed on antigen-presenting cells to reduce their ability to present antigens. Such inhibition of T-cell responses by reducing antigen presentation may therefore contribute to the well-known antiinflammatory effects of IVIg in autoimmune diseases. (Blood. 2010;115:1727-1734)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据